Faropenem
Mechanism :
Faropenem interfere with PBP (penicillin binding protein) activity involved in the final phase of peptidoglycan synthesis. PBPs are enzymes which catalyse a pentaglycine crosslink between alanine and lysine residues providing additional strength to the cell wall. Without a pentaglycine crosslink, the integrity of the cell wall is severely compromised and ultimately leads to cell lysis and death. Eventually faropenem binds to PBP and leads to cell lysis and death.
Indication :
- Uncomplicated skin and skin structure infections
- Community acquired pneumonia
- Acute bacterial sinusitis
- Urinary tract infections
Contraindications :
Efficacy and doses are not known for Paediatric population.
Adult: The recommended dosage of Faropenem is 150 – 200 mg, thrice daily. Based on the clinical response, the dosage can be increased to 200 – 300 mg, thrice daily.
Dosing :
Safety and efficacy not established in children.
Adults: 150-200 mg orally thrice daily. Max: 200-300 mg orally thrice daily.
Adverse Effect :
Diarrhea, nausea, abdominal pain, diarrhea, rash.
Interaction :
Sodium Valproate, Imipenem, Furosemide, Cilastatin: Faropenem may interact with sodium Valproate, imipenem, furosemide and cilastatin.
Hepatic Dose :
No dosage adjustments are recommended.